Dermata Therapeutics, Inc. filings document a dermatology-focused operating company with common stock and publicly traded warrants, a direct-to-consumer skincare strategy and ongoing capital-structure activity. Recent Form 8-K reports cover annual and quarterly operating results, prospectus supplements for at-the-market common stock sales, private financing-related disclosure, and material agreements tied to the company's shift away from pharmaceutical development.
Dermata's proxy and governance filings address shareholder voting matters, board composition and corporate governance. Other current reports document changes in the independent registered public accounting firm, director resignation disclosures, going-concern context in auditor reports, and material-agreement disclosure involving the Villani license and the XYNGARI investigational new drug application.
Dermata Therapeutics, Inc. ownership update: Bigger Capital Fund, LP and related reporting persons disclose beneficial ownership of 75,200 shares of Common Stock, representing 1.87% of the outstanding shares based on 4,022,143 shares outstanding as of March 30, 2026. The filing states this figure excludes multiple warrant positions (including 490,200 Series C and 490,200 Series D issuable shares held by Bigger Capital, and 189,084 DRMAW Public Warrants) that are subject to shareholder approval and a 4.99% beneficial ownership limitation. The Reporting Persons note they sold a portion of their Common Stock, including all Common Stock issuable upon exercise of Pre-Funded Warrants, and state they do not beneficially own at least 5.00% of the issuer as of April 22, 2026.
Dermata Therapeutics, Inc. is asking stockholders to approve seven proposals at its virtual 2026 annual meeting on May 27, 2026. The agenda includes electing three Class II directors to serve until 2029 and ratifying CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2026.
Stockholders are also asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying warrants that could equal or exceed 20% of common stock outstanding before issuance, the repricing of warrants exercisable for up to 120,734 shares, and an increase in the 2021 Omnibus Equity Incentive Plan reserve to 402,214 shares. An adjournment proposal would allow more time to solicit votes if needed.
Only holders of record on March 30, 2026, when 4,022,143 shares of common stock were outstanding, may vote. The meeting will be held exclusively online, and the Board recommends voting FOR all director nominees and FOR Proposals 2 through 6.
Dermata Therapeutics (DRMA) is soliciting proxies for its virtual 2026 Annual Meeting on May 27, 2026 to vote on director elections and several governance and capital-structure proposals. The meeting notice lists seven proposals including: election of three Class II directors; ratification of CBIZ as auditor; approval to issue shares underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock; repricing of warrants exercisable for 120,734 shares; and an increase of the 2021 Plan reserve to 402,214 shares. Shares outstanding were 4,022,143 as of the record date, March 30, 2026. The Board recommends a vote FOR all listed proposals. The meeting will be virtual and stockholders must register to attend and vote.
Dermata Therapeutics, Inc. files its annual report describing a major strategic shift from prescription dermatology to over-the-counter and cosmetic skincare under its new Tome brand. After achieving statistically significant Phase 3 results in 2025 for its acne candidate XYNGARI, the company chose not to pursue the traditional prescription path and instead focus on faster-to-market consumer products.
Dermata plans to commercialize once-weekly Tome Foundational Treatment and a Clearing Treatment acne system built around its proprietary Bioneedle technology, derived from the freshwater sponge Spongilla lacustris. The products are intended to offer skin renewal and acne control with simplified routines and natural ingredients.
The company outlines a dual go-to-market strategy combining direct-to-consumer e-commerce with a professional B2B channel, including a Tome certification program for aestheticians and dermatology practices. It also highlights potential future applications of Bioneedle for broader skin conditions and a paused collaboration using the platform for topical delivery of botulinum toxin.
Dermata Therapeutics reported 2025 results and detailed a strategic pivot from prescription dermatology to direct-to-consumer skincare under its new Tome brand. The first Tome product, a once-weekly Foundational Treatment mask, is planned for launch in the middle of 2026, with a Clearing Treatment for acne expected to follow.
For 2025, Dermata posted a net loss of $7.6 million, improving from a $12.3 million net loss in 2024, as research and development expenses declined to $2.9 million from $8.2 million, largely after completing its STAR-1 acne study. Selling, general and administrative expenses rose to $4.8 million from $4.3 million, mainly due to increased marketing.
Cash and cash equivalents were $7.5 million as of December 31, 2025, up from $3.2 million a year earlier, driven by approximately $12.1 million of net financing proceeds and $7.8 million of cash used in operations. Dermata raised $15.4 million in gross proceeds during 2025 and early 2026 and expects its cash to fund operations into the first quarter of 2027 while it prepares multiple Tome products for market.
Dermata Therapeutics, Inc. senior vice president of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction at $1.27 per share on February 17, 2026. Following this purchase, she holds 1,012 shares directly and 34 shares indirectly through the Munera Family Trust.
Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.
The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.
Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock. This represents 17.3% of the company’s outstanding common stock as of a recent share count.
The filing explains that his holdings include shares and options held directly, shares and warrants held through Proehl Investment Ventures LLC, and shares held by certain trusts for which he serves as trustee. The amendment also notes that there have been no purchases or sales of Dermata common stock or related convertible securities by him or entities he controls since a prior amendment earlier in 2026.
Dermata Therapeutics filing: Armistice Capital and Steven Boyd report shared beneficial ownership of 53,910 shares, representing 4.99% of common stock. The report, filed as a joint Schedule 13G/A, states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and that voting and dispositive power over the shares is exercised pursuant to an Investment Management Agreement. The Master Fund is identified as the direct holder and the filing notes the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the securities under that agreement.